Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Equitable Holdings (EQH)
NYSEFinancialsAsset ManagementSnapshot 2026-11-05
$52.91-5.72%
Close 2026-11-05 · 1-day change
NYSEFinancialsAsset ManagementSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
9.00 → 8.94 EPS · FY ending Dec 31, 2027 · 8 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 9 to 8; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for EQH yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Generate at least $1.8 billion cash in 2026 | Equitable aims to generate $1.8 billion cash in 2026. | Intact | cash generation falls below $1.2 billion in FY26 | Cash from operations: $643M FY2026-Q2; GAAP. Published target: >=1800 USD_MILLIONS. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 2026643,000,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a merger-execution and financial-sector business, with growth targets that management says are on track. The thesis is in a watch state: recent performance is weak, earnings quality is fragile, and management is rated neutral.
EQH is assessed as cheap versus peers, while the priced-in signal is described as justified rather than highly fragile. Valuation rose recently, and the expectations gap is negative, suggesting current expectations remain a concern despite the peer discount.
Near term, management’s stated priorities are progressing: the Corebridge merger remains on track for year-end 2026, and cash generation and earnings-growth goals are reported as on track. Recent results include two earnings beats, but overall financial performance remains weak relative to the industry cohort, and the evidence notes a pattern of recent misses across the name and peers.
Over the next year, the thesis depends on closing the merger on schedule and meeting management’s cash-generation and earnings-growth goals. A guidance cut or lower rates would be unfavorable under the evidence provided, while continued strong results and guidance from major financial-sector peers would support sector momentum.
For the 1-to-3-year view, EQH has clear management milestones and a peer valuation discount, but the weak relative performance and fragile earnings quality leave execution as the central test. The outlook is mixed, with the merger and stated targets still on track. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 3 of 4 supplied quarters. Management reported: “◦ The Company continues to target $1.8 billion of cash generation for 2026 and has received regulatory approval for up to $0.9 billion of insurance company dividends in the second half of the year.” “Looking forward, we remain confident in achieving our 2026 guidance of $1.8 billion of cash generation and over 15% growth in earnings per share,” said Mark Pearson, President and Chief Executive Officer.”
Achieve over 15% EPS growth in 2026 | EPS should grow over 15% this year. | Improving | EPS growth falls below 10% in FY26 | Diluted EPS: $4.05 per share FY2026-Q3; GAAP. Published target: >15% YoY EPS growth. Annual target cannot be compared with a quarterly or TTM observation. Nov 5, 20264.05 USD/share · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 4 supplied quarters. Management reported: “For the first nine months of the year, Non-GAAP operating earnings per share was up 22%, delivering on our guidance for greater than 15% growth in 2026.” “Looking forward, we remain confident in achieving our 2026 guidance of $1.8 billion of cash generation and over 15% growth in earnings per share,” said Mark Pearson, President and Chief Executive Officer.” Delivery assessment Nov 5, 2026 |
Execute announced share buyback program | The company has a share buyback plan. | Intact | Buyback program is canceled or materially reduced | Buyback active (announced 2026-04-16) EQH announced a share buyback on 2026-04-16. Recent news focuses on the Corebridge merger and expense savings, with no mention of buyback cancellation. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$8.92 → $8.94 · observed estimates
$17.12B → $16.72B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $8.92 | $17,116,252,871 | 9 / 5 |
| 2026-07-25 | $8.92 | $16,948,960,130 | 13 / 5 |
| 2026-07-26 | $8.92 | $17,123,022,911 | 9 / 5 |
| 2026-07-27 | $8.93 | $16,903,666,770 | 13 / 6 |
| 2026-07-28 | $8.92 | $17,123,022,911 | 9 / 5 |
| 2026-07-29 | $8.93 | $16,903,666,770 | 13 / 6 |
| 2026-07-30 | $8.93 | $16,903,666,770 | 13 / 6 |
| 2026-07-31 | $8.92 | $17,123,024,322 | 8 / 5 |
| 2026-08-01 | $8.92 | $17,123,024,322 | 8 / 5 |
| 2026-08-02 | $8.93 | $16,904,166,770 | 13 / 6 |
| 2026-08-03 | $8.93 | $16,904,166,770 | 13 / 6 |
| 2026-08-04 | $8.92 | $17,123,357,655 | 8 / 5 |
| 2026-08-05 | $8.93 | $16,904,166,770 | 13 / 6 |
| 2026-08-06 | $8.92 | $17,123,357,655 | 8 / 5 |
| 2026-08-07 | $8.98 | $16,622,468,766 | 8 / 5 |
| 2026-08-08 | $8.99 | $17,043,571,520 | 13 / 7 |
| 2026-08-09 | $8.99 | $17,043,571,520 | 13 / 7 |
| 2026-08-10 | $8.98 | $16,622,468,766 | 8 / 5 |
| 2026-08-11 | $8.99 | $17,043,571,520 | 13 / 7 |
| 2026-08-12 | $8.99 | $17,055,557,229 | 13 / 7 |
| 2026-08-13 | $8.99 | $17,055,557,229 | 13 / 7 |
| 2026-08-14 | $8.98 | $16,622,468,766 | 8 / 5 |
| 2026-08-15 | $8.98 | $16,622,468,766 | 8 / 5 |
| 2026-08-16 | $8.98 | $16,622,468,766 | 8 / 5 |
| 2026-08-17 | $8.98 | $16,622,468,766 | 8 / 5 |
| 2026-08-18 | $8.98 | $16,622,468,766 | 8 / 5 |
| 2026-08-19 | $8.98 | $16,622,468,766 | 8 / 5 |
| 2026-08-20 | $9.00 | $16,696,157,852 | 9 / 6 |
| 2026-08-21 | $9.00 | $16,696,157,852 | 9 / 6 |
| 2026-08-22 | $9.00 | $16,696,157,852 | 9 / 6 |
| 2026-08-23 | $8.94 | $16,559,072,588 | 9 / 6 |
| 2026-08-24 | $8.94 | $16,559,072,588 | 9 / 6 |
| 2026-08-25 | $8.94 | $16,751,754,873 | 9 / 6 |
| 2026-08-26 | $8.94 | $16,751,754,873 | 9 / 6 |
| 2026-08-27 | $8.94 | $16,751,754,873 | 9 / 6 |
| 2026-08-28 | $8.94 | $16,751,754,873 | 9 / 6 |
| 2026-08-29 | $8.94 | $16,751,754,873 | 9 / 6 |
| 2026-08-30 | $8.94 | $16,751,754,873 | 9 / 6 |
| 2026-08-31 | $8.94 | $16,751,754,873 | 9 / 6 |
| 2026-09-01 | $8.94 | $16,751,754,873 | 9 / 6 |
| 2026-09-02 | $8.94 | $16,751,754,873 | 9 / 6 |
| 2026-09-03 | $8.94 | $16,751,754,873 | 9 / 6 |
| 2026-09-04 | $8.94 | $16,751,754,873 | 9 / 6 |
| 2026-09-05 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-06 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-07 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-08 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-09 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-10 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-11 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-12 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-13 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-14 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-15 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-16 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-17 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-18 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-19 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-20 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-21 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-22 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-23 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-24 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-25 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-26 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-27 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-28 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-29 | $9.01 | $16,875,033,609 | 9 / 6 |
| 2026-09-30 | $9.00 | $16,875,033,609 | 9 / 6 |
| 2026-10-01 | $9.00 | $16,875,033,609 | 9 / 6 |
| 2026-10-02 | $9.00 | $16,875,033,609 | 9 / 6 |
| 2026-10-03 | $9.00 | $16,875,033,609 | 9 / 6 |
| 2026-10-04 | $9.00 | $16,875,033,609 | 9 / 6 |
| 2026-10-05 | $9.00 | $16,875,033,609 | 9 / 6 |
| 2026-10-06 | $9.00 | $16,875,033,609 | 9 / 6 |
| 2026-10-07 | $9.01 | $16,843,900,507 | 9 / 6 |
| 2026-10-08 | $9.01 | $17,372,567,175 | 8 / 6 |
| 2026-10-09 | $9.01 | $17,372,567,175 | 8 / 6 |
| 2026-10-10 | $9.01 | $17,372,567,175 | 8 / 6 |
| 2026-10-11 | $8.99 | $17,352,010,208 | 8 / 6 |
| 2026-10-12 | $8.99 | $17,352,010,208 | 8 / 6 |
| 2026-10-13 | $8.99 | $17,344,731,444 | 8 / 6 |
| 2026-10-14 | $8.98 | $17,344,698,111 | 8 / 6 |
| 2026-10-15 | $8.98 | $17,344,698,111 | 8 / 6 |
| 2026-10-16 | $8.97 | $17,344,698,111 | 8 / 6 |
| 2026-10-17 | $8.97 | $17,344,698,111 | 8 / 6 |
| 2026-10-18 | $8.97 | $17,344,698,111 | 8 / 6 |
| 2026-10-19 | $8.97 | $17,344,698,111 | 8 / 6 |
| 2026-10-20 | $8.97 | $17,344,698,111 | 8 / 6 |
| 2026-10-21 | $8.97 | $17,344,698,111 | 8 / 6 |
| 2026-10-22 | $8.97 | $17,344,698,111 | 8 / 6 |
| 2026-10-23 | $8.97 | $17,344,698,111 | 8 / 6 |
| 2026-10-24 | $8.97 | $17,344,698,111 | 8 / 6 |
| 2026-10-25 | $8.97 | $17,344,698,111 | 8 / 6 |
| 2026-10-26 | $8.98 | $17,348,265,222 | 8 / 6 |
| 2026-10-27 | $8.98 | $17,348,265,222 | 8 / 6 |
| 2026-10-28 | $8.98 | $17,348,264,777 | 8 / 6 |
| 2026-10-29 | $8.98 | $17,348,264,777 | 8 / 6 |
| 2026-10-30 | $8.98 | $17,348,264,777 | 8 / 6 |
| 2026-10-31 | $8.96 | $16,794,709,222 | 8 / 6 |
| 2026-11-01 | $8.96 | $16,794,709,222 | 8 / 6 |
| 2026-11-02 | $8.96 | $16,794,709,665 | 8 / 6 |
| 2026-11-03 | $8.96 | $16,794,709,662 | 8 / 6 |
| 2026-11-04 | $8.94 | $16,724,113,591 | 8 / 6 |
| 2026-11-05 | $8.94 | $16,724,113,591 | 8 / 6 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 11 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 4 recorded
2 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.